Retrospective Register for Uveal Melanoma

Status Recruiting

Clinical Trial Summary

Background: Uveal melanoma (UM) is a common primary ocular malignancy associated with limited overall survival in the advanced stage of the disease. Fundamental breakthrough regarding the management of the disease and the overall-survival have not yet been achieved. Studies with large cohorts are difficult to perform due to limited patient numbers, therefore retrospective analyses are of great potential to gain further knowledge in a disease with high clinical needs. Aim: The proposed project is a register for patients with UM treated at the Department of Ophthalmology and Optometry at the Medical University of Vienna between 01.01.1997 and 31.12.2021. Patients and Methods: Patients treated for UM at the Department of Ophthalmology and Optometry at the Medical University of Vienna between 01.01.1997 and 31.12.2021 will be included in the register. Information on the baseline characteristics, survival times and course of the disease will be gathered via retrospective chart review and saved in a password-secured database.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05733728
Study type	Observational [Patient Registry]
Source	Medical University of Vienna
Contact	Reinhard Told
Phone	+4314040048470
Email	reinhard.told@meduniwien.ac.at
Status	Recruiting
Phase
Start date	January 23, 2023
Completion date	December 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04364230` - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	Phase 1/Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Active, not recruiting	`NCT05542342` - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.	Phase 2
Completed	`NCT02849145` - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)	N/A
Recruiting	`NCT01438658` - Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma	N/A
Not yet recruiting	`NCT00811200` - Treatment Of Radiation Retinopathy Trial	Phase 2/Phase 3
Completed	`NCT00121225` - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma	Phase 2
Recruiting	`NCT05077280` - A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma	Phase 2
Completed	`NCT03297424` - A Study of PLX2853 in Advanced Malignancies.	Phase 1
Withdrawn	`NCT05482074` - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2	Phase 2
Completed	`NCT04551352` - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	Phase 1
Not yet recruiting	`NCT06246149` - Adjuvant Tebentafusp in High Risk Ocular Melanoma	Phase 3
Completed	`NCT01955941` - Vascular Response to Brachytherapy Using Functional OCT
Completed	`NCT00661622` - Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF	Phase 2
Recruiting	`NCT05502900` - Adjuvant Melatonin for Uveal Melanoma	Phase 3
Active, not recruiting	`NCT03070392` - Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma	Phase 2
Recruiting	`NCT06284512` - Uveal Melanoma - Comparative Study
Recruiting	`NCT05524935` - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	Phase 2
Active, not recruiting	`NCT02913417` - Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases	Phase 1/Phase 2
Not yet recruiting	`NCT06073548` - Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study